Lexicon Pharma spikes after insider buy
Source: SeekingAlpha
2026-02-19 11:46:50 ET
More on Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
- Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well
- Lexicon Pharmaceuticals prices $94.6M share offering
- Lexicon Pharmaceuticals launches underwritten public stock offering
Read the full article on Seeking Alpha
For further details see:
Lexicon Pharma spikes after insider buy
Lexicon Pharmaceuticals Inc.
NASDAQ: LXRX
LXRX Trading
1.75% G/L:
$1.745 Last:
2,103,454 Volume:
$1.69 Open:
LXRX Latest News
March 05, 2026 06:59:00 am
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
March 03, 2026 04:01:00 pm
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
LXRX Stock Data
$557,345,360
216,958,960
0.2%
137
N/A
Biotechnology & Life Sciences
Healthcare
US
The Woodlands
